Data base for:

  • Conferences
  • Research funding opportunities
  • Competitions / Awards

Register for free and add any data by yourself!

Filter conferences

 
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
 
      
      
 
      
 
      
      
      
      
      
      
      
      
      
      
Gastrointestinal (GI) Cancer Drug Development Summit - FREE FOR DRUG DEVELOPERS, RESEARCHERS & NFP

Gastrointestinal (GI) Cancer Drug Development Summit - FREE FOR DRUG DEVELOPERS, RESEARCHERS & NFP

Categories

Date of beginning

Tuesday, 02 November 2021

Duration

3 days

City

Online

Country

United States

Contact

Customer Service

E-Mail

This email address is being protected from spambots. You need JavaScript enabled to view it.

Memo

Welcome to the Gastrointestinal (GI) Cancer Drug Development Summit - The only biopharma-led conference dedicated to identifying and progressing therapeutic opportunities in targeted and immunotherapies, ADCs, and precision oncology to address the large unmet clinical need in GI cancers. **This meeting is free-to-attend for drug developers, research institutions, and not-for-profit organizations**. Explore the full conference guide here: https://ter.li/rkdp17 This industry-dedicated meeting offers a comprehensive insight into developing optimal clinical programs for targeted, immune, and ADC therapies in these solid tumors. Join us and our 39+ expert speaker faculty as we navigate cancer heterogeneity and develop biomarker-driven enrichment strategies to direct better treatments to specific patient subsets and invest in rationale therapeutic combination approaches for this vastly unmet clinical need. Whether your group is targeting microsatellite instable (MSI) and stable (MSS) CRC, a rare GI malignancy or treatment-resistant HCC, this unique forum is your opportunity to establish clinical collaborations, plan new combinatorial studies and assess how a future drug candidate can change the clinical landscape. To learn more view our complete event guide: https://ter.li/rkdp17 **A "drug developer” or “researcher” must have a pipeline candidate and/or work for an academic institution, and must not provide solutions or services for a fee to any other company. All bookings under the drug developer/researcher category are subject to organizer approval. Brochure https://go.evvnt.com/808745-0?pid=5569Tickets https://go.evvnt.com/808745-2?pid=5569 Prices: USD 0.00 Speakers: Edward Cha, Global Development Lead, GI CANCERS & COMBINATIONS, Genentech, Giovanni Abbedessa, Global Head of Oncology Early Development, & Global Project Head, peg-IL-2 (THOR-707 / SAR444245), Sanofi Genzyme, Eric Murphy, Co-Founder & Chief Scientific Officer, Kinnate Biopharma Inc., Linh Alejandro, Adagrasib GI Medical Lead, Mirati Therapeutics, Valerie Jansen, Vice President - Clinical Development, Elevation Oncology, Tim Demuth, Vice President & Head of Global Clinical Development Oncology, Merck KGaA, Jian Chen, Director - Translational Research, Sandhill Therapeutics , Harish Dave, Co-Founder & Chief Medical Officer, AUM Biosciences , Shane Olwill, Senior Vice President & Head of Translational Science, Pieris Pharmaceuticals AG, Reva Basho, Medical Oncologist, Cedars-Sinai Medical Center, Brian Tunquist, Director, Companion Diagnostics, Pfizer, Timothy Chen, Director - Discovery & Cell Biology, Maverick Therapeutics, Hiranmayi Ravichandran, Mass Cytometry Specialist & Research Associate, Weill Cornell Medical College, Xing-Jian Lou, Program Director, National Cancer Institute, Afsaneh Barzi, Associate Professor of Medical Oncology, City of Hope-Director of Employer Health, Access-Hope, Chief Medical Advisor, Cardiff Oncology , Jeroen Lammerts Van Bueren, Senior Director - Translational Science, Merus NV, Roxana Schillaci, Senior Researcher, Instituto de Biología y Medicina Experimental, Buenos Aires (IBYME), Mallika Singh, VP, Translational Research, Revolution Medicines, Nataliya Uboha, Assistant Professor, University of Wisconsin-Madison, Volker Schellenberger, President & Chief Executive Officer, Amunix Pharmaceuticals Inc., Lauren Leiman, Executive Director, BloodPAC, Angelica Loskog, Chief Executive Officer, Lokon Pharma AB, Ting Xu, Chairman, Chief Executive Offier, Executive Director & Founder, Alphamab Oncology, Jason Christiansen, Chief Technology Officer, Boundless Bio, Laura Davison, Research Scientist, TeneoBio, Thomas Tan, Chief Scientific Officer, Bicara Therapuetics, Muhammad Shaalan Beg, Associate Professor & Assistant Director - Gastrointestinal Medical & Oncology, Internal Medicine, Gastrointestinal Co-Leader, UT Southwestern, Elizabeth Smyth, Clinical Consultant, Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Berke Olcaysoy, Molecular Biologist, Acibadem Healthcare Group, Benny Johnson, Assistant Professor- Gastrointestinal & Medical Oncology, MD Anderson Cancer Center, Kamala K Maddali, President & Founder, Health Collaborations LLC Date and Time: Starts: Tue, Nov 2, 2021 at 8:30 AM and Ends: Thu, Nov 4, 2021 at 5:00 PM